Viral Vector Manufacturing Facility Pty Ltd (VVMF) announces its participation at Advanced Therapies Week 2026, 9 – 12 February 2026, in San Diego, USA.
VVMF Head of Business Development and Partnerships, Anita van der Meer, will be available to discuss VVMF’s expertise in process development, viral vector manufacturing, and the wrap-around services to leverage the advantages of the Australian biotechnology ecosystem.
Committed to supporting biotech and pharmaceutical companies, VVMF delivers high-quality lentiviral (rLV) and adeno-associated viral (rAAV) vector solutions tailored to their research, clinical, and commercial needs.
Backed by leading scientific and clinical expertise, VVMF provides a strategic advantage – further strengthened by Australia’s 43.5% R&D tax incentive for eligible companies.
VVMF’s Anita van der Meer shared, “The Advanced Therapies Week event is built around today’s industry challenges. It’s a great opportunity to connect and build new relationships within the global Cell & Gene therapy sector. I look forward to discussing how VVMF can be your trusted partner in advancing cell and gene therapies.”
Schedule a meeting via the ATW – Phacilitate Event App or info@vvmf.com.au
Unlocking the future of medicine – with strong connections built at Advanced Therapies Week 2026.